PCSA
Price:
$0.871
Market Cap:
$2.85M
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, wh...[Read more]
Industry
Biotechnology
IPO Date
2014-03-07
Stock Exchange
NASDAQ
Ticker
PCSA
According to Processa Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.18. This represents a change of -73.28% compared to the average of -0.67 of the last 4 quarters.
The mean historical PE Ratio of Processa Pharmaceuticals, Inc. over the last ten years is -16.75. The current -0.18 PE Ratio has changed 7.49% with respect to the historical average. Over the past ten years (40 quarters), PCSA's PE Ratio was at its highest in in the March 2023 quarter at 17.05. The PE Ratio was at its lowest in in the December 2018 quarter at -57.16.
Average
-16.75
Median
-5.44
Minimum
-77.26
Maximum
-0.32
Discovering the peaks and valleys of Processa Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 842.47%
Maximum Annual PE Ratio = -0.32
Minimum Annual Increase = -95.08%
Minimum Annual PE Ratio = -77.26
Year | PE Ratio | Change |
---|---|---|
2023 | -0.79 | 144.10% |
2022 | -0.32 | -95.08% |
2021 | -6.57 | 91.43% |
2020 | -3.43 | -88.40% |
2019 | -29.58 | -17.13% |
2018 | -35.69 | -53.81% |
2017 | -77.26 | 842.47% |
2016 | -8.20 | 524.24% |
2015 | -1.31 | -69.50% |
2014 | -4.31 | 4.91% |
The current PE Ratio of Processa Pharmaceuticals, Inc. (PCSA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.56
5-year avg
-8.14
10-year avg
-16.75
Processa Pharmaceuticals, Inc.’s PE Ratio is greater than Alpha Cognition Inc. (-2.34), greater than Eupraxia Pharmaceuticals Inc. (-6.61), less than Acurx Pharmaceuticals, Inc. (-0.01), greater than Fennec Pharmaceuticals Inc. (-140.49), less than Comera Life Sciences Holdings, Inc. (-0.00), greater than SAB Biotherapeutics, Inc. (-0.83), greater than Fresh Tracks Therapeutics, Inc. (-3.09), greater than Third Harmonic Bio, Inc. (-10.88), less than Eliem Therapeutics, Inc. (0), less than Inhibrx Biosciences, Inc. (0.14), greater than Merrimack Pharmaceuticals, Inc. (-8.92), greater than Celcuity Inc. (-5.71), greater than Enliven Therapeutics, Inc. (-13.11), greater than AN2 Therapeutics, Inc. (-0.67), greater than Miromatrix Medical Inc. (-7.13), greater than Inhibikase Therapeutics, Inc. (-1.34), greater than PMV Pharmaceuticals, Inc. (-1.47), greater than Anebulo Pharmaceuticals, Inc. (-5.30), greater than Akari Therapeutics, Plc (-0.61), greater than Armata Pharmaceuticals, Inc. (-1.76), less than Scopus BioPharma Inc. (-0.00),
Company | PE Ratio | Market cap |
---|---|---|
-2.34 | $35.66M | |
-6.61 | $108.29M | |
-0.01 | $14.78M | |
-140.49 | $169.78M | |
-0.00 | $6.15K | |
-0.83 | $37.84M | |
-3.09 | $4.42M | |
-10.88 | $465.00M | |
0 | $342.68M | |
0.14 | $209.76M | |
-8.92 | $223.97M | |
-5.71 | $465.23M | |
-13.11 | $1.13B | |
-0.67 | $40.64M | |
-7.13 | $92.95M | |
-1.34 | $198.89M | |
-1.47 | $76.07M | |
-5.30 | $42.01M | |
-0.61 | $11.90M | |
-1.76 | $72.73M | |
-0.00 | $12.63K |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Processa Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Processa Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Processa Pharmaceuticals, Inc.'s PE Ratio?
How is the PE Ratio calculated for Processa Pharmaceuticals, Inc. (PCSA)?
What is the highest PE Ratio for Processa Pharmaceuticals, Inc. (PCSA)?
What is the 3-year average PE Ratio for Processa Pharmaceuticals, Inc. (PCSA)?
What is the 5-year average PE Ratio for Processa Pharmaceuticals, Inc. (PCSA)?
How does the current PE Ratio for Processa Pharmaceuticals, Inc. (PCSA) compare to its historical average?